Vergelijking

Icatibant vs. Octreotide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

138614-30-9

83150-76-9

Molecuulmassa

1304.52 g/mol

1019.24 g/mol

Halfwaardetijd

geen gegevens

1.7 h

Sequentie

geen gegevens

D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)

Werkingsmechanisme

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Octreotide

Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Icatibant	Octreotide
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Icatibant

Volledige vermelding →

Octreotide

Volledige vermelding →

Frequently asked questions

What is the difference between Icatibant and Octreotide?: Icatibant is classified as "Onderzoek (overig)", while Octreotide is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Octreotide?: The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Octreotide in Germany and the United States?: Duitsland: Icatibant — Op recept, Octreotide — Op recept. Verenigde Staten: Icatibant — Op recept, Octreotide — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Octreotide

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Icatibant and Octreotide?

Icatibant is classified as "Onderzoek (overig)", while Octreotide is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Octreotide?

The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Octreotide in Germany and the United States?

Duitsland: Icatibant — Op recept, Octreotide — Op recept. Verenigde Staten: Icatibant — Op recept, Octreotide — Op recept. These are factual summaries with source and review date on the individual pages.